Scotiabank raised the firm’s price target on Disc Medicine (IRON) to $70 from $62 and keeps an Outperform rating on the shares. The firm views the company’s end-of-phase 2 FDA meeting update as a “home run” given alignment on all proposed endpoints for its phase 3 trial design to assess bitopertin, the analyst tells investors. The trial will assess bitopertin in erythropoietic protoporphyria and X-linked protoporphyria and, while the two are rare, the firm believes bitopertin will capture meaningful market share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Disc Medicine upgraded to Overweight from Equal Weight at Morgan Stanley
- Disc Medicine price target raised to $112 from $70 at BMO Capital
- Disc Medicine upgraded at Raymond James as bitopertin ‘uber bull case plays out’
- Disc Medicine upgraded to Strong Buy from Outperform at Raymond James
- Disc Medicine Gains FDA Support for Bitopertin Trial